Listen to article
6:16Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Published on 2 October 2026
Read article
Let’s be honest, the idea of printing a human heart on demand sounds like something lifted from a pulpy science fiction novel. For years, it has been exactly that, a fantastical concept confined to laboratories and optimistic press releases. I’ve seen countless ‘next big things’ in medicine fizzle out. Yet, every so often, a technology turns a corner so sharply that even a cynic like me has to sit up and pay attention. Bioprinting, it seems, has just turned that corner.
For the longest time, the entire field was stuck on a rather fundamental problem. Scientists could print small, simple bits of tissue, but anything more complex would simply die from the inside out. It was like building a magnificent city but forgetting to install any roads, plumbing, or electricity. The cells in the middle, starved of oxygen and nutrients, would perish. The whole endeavour was, quite literally, dead on arrival.
The breakthrough, the moment this all changed, was the successful printing of vascular networks. Blood vessels. The tiny, intricate highways that deliver life to every part of the body. Cracking this code means we can now, potentially, build tissues that can sustain themselves. This isn't just an incremental improvement. It’s the difference between a clever party trick and a genuine revolution in medicine. We’re no longer just talking about skin grafts, we’re talking about the building blocks for hearts, livers, and kidneys.
While the headline-grabbing goal is to solve the global organ shortage, and a noble goal it is, the more immediate impact might be felt elsewhere. Think about the pharmaceutical industry. It spends eye-watering sums, billions upon billions, developing new drugs. A shocking number of these drugs fail late in the game when they are finally tested on humans, after showing great promise in animal trials. Why? Because a mouse, last I checked, is not a tiny human.
Now, imagine you could test a new heart medication on a piece of 3D-printed human heart tissue. Not a mouse heart, not a simplified cell culture, but the real deal. The potential to weed out failures earlier, reduce development costs, and get effective treatments to patients faster is enormous. It could fundamentally change the economics of drug discovery, a market that makes the organ transplant market look like a corner shop.
So, how does one invest in this future? Cautiously, I would suggest. This is the very definition of high-risk, high-reward. For every company that succeeds, several others will likely fall by the wayside, burning through cash with little to show for it. The path from a lab to a commercially viable, regulator-approved product is long, expensive, and fraught with peril.
This isn’t the sort of thing you bet the farm on. It’s a satellite holding, an educated punt on a transformative technology. For most of us, picking individual winners in this complex field is a fool's errand. It's why gaining exposure through a collection of companies, like those in a 3D-Bioprinted Tissues theme, could make more sense. It spreads the risk, acknowledging that the rising tide of the technology itself, rather than a single company’s fortune, is the real story here. The potential is undeniable, but so are the risks, and anyone telling you otherwise is selling something.
View the full Basket:3D-Bioprinted Tissues
View the full Basket:3D-Bioprinted Tissues
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Published on 2 October 2026
Read article
